Detecting cancer has become increasingly imperative to it. Cervical cancer is the fourth most common type of cancer prevailing among women. Human papillomavirus test (HPV test) is performed to detect the presence of a virus that can cause cervical and HPV-related cancers. Globally, Human Papillomavirus testing is used as a screening test for cervical cancer, but the test detects only the presence of HPV. The Human Papillomavirus testing market is likely to grow mainly due to the rising prevalence of cervical cancer and HPV associated infections that lead to cancers, the growing demand for the nucleic acid test, and the rising awareness of HPV testing.

Prevalence of Cervical Cancers

In 2019, the cervical application segment accounted for over 87% share of the global HPV testing market. The market is expected to grow at a significant rate due to the rapid use of Human Papillomavirus tests with instruments, utilization of consumables for cervical screening and the growing incidence of cervical cancer cases. According to the WHO, approximately 570,000 cervical cancer cases were diagnosed in 2018 across the globe. The rates are high in developing countries, approximately 85% of cases and related deaths take place among women living in lower-middle-income countries (LMICs). Human Papillomavirus testing improves the specificity of screening programs, which helps to avoid overtreatment and promotes cost savings for confirmatory procedures. Key market players offer innovative HPV testing instruments and consumables for cervical screening, which help to identify the patients that might develop cervical cancer in the future.

Request for your free sample now!

The Rise of Vaginal Cancer

In 2019, the vaginal application segment accounted for over 7% share of the global Human Papillomavirus testing market. The market is expected to grow primarily on account of the growing incidence of vaginal cancers and the increasing usage of HPV testing for vaginal screening. Human papillomavirus plays a major role in the pathogenesis of vaginal cancer and affects 90–100% of vaginal intraepithelial neoplasia (VaIN) and 60–70% of vaginal squamous cell carcinomas (SCC). The American Cancer Society stated that approximately 5,350 new cases of vaginal cancer were diagnosed in the US alone in 2019.

Human Papillomavirus testing for vaginal cancer offers a powerful negative predictive value. Therefore, the detection of high-risk HPV infection, which produces visible signs, is likely a powerful tool for vaginal screening. Market players are expected to offer innovative HPV testing devices owing to the benefits of Human Papillomavirus testing accompanied by the growing vaginal cancer burden.

Geographical Overview

North America accounted for over 56% share of the global HPV Testing market in 2019. The region is expected to generate high growth owing to increased awareness levels, increased healthcare expenditures, coupled with reimbursement coverage and high affordability. Further, the market is driven by advanced technology and a high adoption rate of these technologies. Europe accounted for over 23% of share in 2019. The UK, France, Germany, Italy, and Spain are likely to be major revenue generators in the region because of the growing awareness of HPV tests for cervical cancer screening along with improved healthcare infrastructure, favorable guidelines, and the availability of technologically advanced Human Papillomavirus testing instruments and test kits.

According to the IMF World Economic Outlook database projections, the GDP of Asia increased from 5.3% in 2016 to 5.4% in 2018. The Japanese government healthcare expenditure increased from 20.12% in 2013 to 20.28% in 2014, and government agencies in emerging economies of APAC have also increased their healthcare expenditures such factors are expected to propel the market in this region at a steady pace. However, the incidence of cervical cancer is rising in the region and the lack of infrastructure and awareness is expected to hinder the growth for HPV testing market.

Request for your free sample now!

You may reach us at

enquiry@arizton.com